Search
Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigational[A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. … This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesLancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … Human papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONGallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.
Categories: Compounds used in a research, industrial, or household settingCemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872] … [L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
Deserpidine
go.drugbank.com/drugs/DB01089ApprovedWithdrawnDeserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure … and for the relief of psychotic behavior.
Hydroxyamphetamine
go.drugbank.com/drugs/DB09352ApprovedAmong the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary … Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.
Cefmenoxime
go.drugbank.com/drugs/DB00267ApprovedCefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use